Insurance impacts survival for children, adolescents, and young adults with bone and soft tissue sarcomas

Neela L. Penumarthy | Robert E. Goldsby | Stephen C. Shiboski | Rosanna Wustrack | Patricia Murphy | Lena E. Winestone

Division of Bioethics and Palliative Care, Department of Pediatrics, University of Washington School of Medicine, Seattle Children’s Hospital, Seattle, WA, USA

Division of Oncology, Department of Pediatrics, UCSF Benioff Children’s Hospital, San Francisco, CA, USA

Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA

Department of Epidemiology and Biostatistics, UCSF, San Francisco, CA, USA

Department of Orthopaedic Surgery, UCSF, San Francisco, CA, USA

Division of Allergy, Immunology, and BMT, Department of Pediatrics, UCSF Benioff Children’s Hospital, San Francisco, CA, USA

Correspondence
Lena E. Winestone, 1975 Fourth St., Sixth Floor, San Francisco, CA 94158, USA.
Email: Lena.winestone@ucsf.edu

Funding information
Funding provided by Alex’s Lemonade Stand and Swim Across America. This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 TR001872. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

Abstract

Background: While racial/ethnic survival disparities have been described in pediatric oncology, the impact of income has not been extensively explored. We analyzed how public insurance influences 5-year overall survival (OS) in young patients with sarcomas.

Methods: The University of California San Francisco Cancer Registry was used to identify patients aged 0-39 diagnosed with bone or soft tissue sarcomas between 2000 and 2015. Low-income patients were defined as those with no insurance or Medicaid, a means-tested form of public insurance. Survival curves were computed using the Kaplan-Meier method and compared using log-rank tests and Cox models. Causal mediation was used to assess whether the association between public insurance and mortality is mediated by metastatic disease.

Results: Of 1106 patients, 39% patients were classified as low-income. Low-income patients were more likely to be racial/ethnic minorities and to present with metastatic disease (OR 1.96, 95% CI 1.35-2.86). Low-income patients had significantly worse OS (61% vs 71%). Age at diagnosis and extent of disease at diagnosis were also independent predictors of OS. When stratified by extent of disease, low-income patients consistently had significantly worse OS (localized: 78% vs 84%, regional: 64% vs 73%, metastatic: 23% vs 30%, respectively). Mediation analysis indicated that metastatic disease at diagnosis mediated 15% of the effect of public insurance on OS.

Conclusions: Low-income patients with bone and soft tissue sarcomas had decreased OS regardless of disease stage at presentation. The mechanism by which insurance status impacts survival requires additional investigation, but may be through reduced access to care.

Keywords
AYA, cancer disparities, health insurance, pediatrics, sarcoma
1 | BACKGROUND

Racial and ethnic survival disparities have been described for many pediatric malignancies. These differences are suspected to be due, in part, to differences in tumor biology, as inferior outcomes have been demonstrated in certain ethnic groups independent of socioeconomic status (SES). However, tumor biology alone cannot explain these survival disparities. In studies of adult cancer, poverty has been shown to contribute to survival disparities through diminished access to health care, resulting in delays in diagnosis and treatment and leading to presentation with advanced disease that is more difficult to cure. The impact of SES has not been extensively explored in the pediatric cancer setting.

While sarcomas are very rare among adult malignancies, they represent 12%-15% of all pediatric tumors, with approximately 1700 children and young adults diagnosed yearly in the United States. They comprise a heterogeneous group of tumors, categorized according to their tissue of origin (soft tissue or bone), and are treated with a combination of surgery and/or radiotherapy to achieve local control, and chemotherapy directed toward occult or overt metastatic disease. Despite improvements in outcomes over the last four decades due to use of multimodal therapy—an approach informed by the work of multi-institutional cooperative groups—approximately one-third of patients, nonetheless, succumb to their disease.

To assess whether SES affects pediatric sarcoma outcomes, we evaluated low-income public health insurance as a proxy for income. Medicaid is a state and federally funded program which provides health insurance to low-income patients; coverage is available under state law to eligible low-income individuals or families. We analyzed how low-income public health insurance influenced overall survival (OS) in children, adolescents, and young adults diagnosed with bone and soft tissue sarcomas.

2 | METHODS

We performed a retrospective analysis of data from the University of California San Francisco Cancer Registry. Patients were included if they were diagnosed with bone or soft tissue sarcoma between 2000 and 2015 and if they were aged between 0 and 39 years at the time of their diagnosis. We identified 1123 potentially eligible records. Of these, six were excluded because they were incorrectly categorized as sarcoma and 11 were excluded because insurance status was unknown. A total of 1106 records were available for complete analysis.

Our two primary outcomes of interest were OS and stage of disease at diagnosis. Stage of disease was coded as localized, regional, or metastatic according to American Joint Committee on Cancer (AJCC) staging assessments. The primary exposure of interest was health insurance type, defined in the University of California San Francisco Cancer Registry as the primary insurance carrier or method of payment at diagnosis.

In the UCSF Cancer Registry, data on patient demographics, primary tumor site, tumor morphology and stage at diagnosis, and follow-up for vital status are routinely collected. The UCSF Cancer Registry classifies race based on information from the medical record. Hispanic ethnicity was determined using stated ethnicity in the medical record, national origin on the death certificate, spoken language, place of birth, and surname. For this analysis, race and ethnicity were considered a compound variable; patients were grouped into five different groups: white non-Hispanic, white Hispanic, Asian non-Hispanic (Asian), African American non-Hispanic (African American), and American Indian. Bone and soft tissue sarcomas encompass a diverse array of histologic subtypes, with heterogeneity in prognosis and treatment; we performed a subgroup analysis of patients with the four most common histologic subtypes. Treatment data, including method of local control, were inconsistently collected. Thus, treatment modality variables were not included in the analysis.

2.1 | Statistical analyses

We extracted raw data and imported into Stata 15 (StataCorp, College Station, TX) for analysis. We calculated descriptive statistics for patient and tumor characteristics, and evaluated differences between groups using Chi-square tests. We defined OS based on all-cause mortality from diagnosis, with survival times calculated as the number of months between date of diagnosis and death. We assigned censoring times for surviving individuals using the date of last follow-up, or 31 December 2015. We summarized OS using Kaplan-Meier estimates with 95% confidence intervals. We evaluated between-group differences using the log-rank test. We generated Kaplan-Meier plots for all patients and according to the extent of disease at presentation (localized, regional, or metastatic). The median follow-up time for the analyzed cohort was 59 months. We truncated Kaplan-Meier plots at 200 months. However, all available data were used in estimates of distributions and group comparisons.

We used univariate and multivariable Cox regression to evaluate predictors of OS; covariates included sex, age (<15 years, 15-29 years, or >29 years of age), race/ethnicity, and disease stage at diagnosis. We performed subgroup analysis of patients with the four most common histologic subtypes, and adjusted for covariates listed above, as well as histology. Covariates were chosen a priori based on the literature and on the potential for confounding. We used hazard
ratios (HR) and 95% confidence intervals to evaluate these covariates as predictors of OS. The proportional hazards assumption was evaluated using Schoenfeld residuals after fitting all Cox models. To evaluate whether the impact of insurance was greater among patients with more advanced disease, we performed a test of interaction on the multiplicative scale between low-income public insurance and stage of disease at diagnosis.

To evaluate the potential impact of excluding patients missing stage of disease at diagnosis, we used chained multiple imputation techniques to fill in missing values based on modeled relationships with other analysis variables. This approach to missing data has been validated by a number of simulation studies and has been employed in studies utilizing population-based cancer registry data. Stage of disease at diagnosis had 17% missing data, and was the only imputed variable.

In order to evaluate the hypothesis that the association between public insurance status and mortality is mediated by the presence of metastatic disease, we used methods for causal mediation analysis. This approach is similar to the standard Baron and Kenny method for linear regression models, but is appropriate for nonlinear models for binary and survival outcomes, and incorporates a more flexible means for control of possible confounding variables.

As a prerequisite for mediation, we considered whether patients with public insurance were more likely to present with advanced stage disease. Logistic regression was used to assess the relationship between insurance and disease stage at diagnosis. Once confirmed, we included public insurance status as the primary predictor variable, and the presence of metastatic disease as the mediator, both represented as binary indicators. These variables were included in a parametric survival regression model for the OS outcome, which was assumed to follow a Weibull distribution, with surviving individuals treated as censored. The relationship between public insurance status and the presence of metastases (the mediator) was modeled with logistic regression. Both models adjusted for age at diagnosis, race vs non-white race, and gender (male vs female) as possible confounding factors. Results were summarized as the estimated percentage of the effect of having public insurance on OS mediated by the presence of metastatic disease with a 95% confidence interval.

All statistical comparisons were two-sided and significance was achieved at level $P < .05$.

### 3 RESULTS

#### 3.1 Patient and tumor characteristics

The study population included 1106 patients. Insurance type was coded as uninsured ($n = 8$), any low-income public insurance (Total [$n = 420$]: Medicaid [$n = 318$], Medicaid through managed care [$n = 53$], county funded [$n = 20$], Indian/public health service [$n = 14$], Medicare with Medicaid supplement [$n = 15$]), or private insurance (Total [$n = 678$]: HMO [$n = 104$], PPO [$n = 136$], managed care [$n = 415$], Tricare [$n = 6$], Medicare [$n = 11$], fee-for-service [$n = 3$], military coverage [$n = 3$]). Given the small number of uninsured patients, these patients were included in the low-income public insurance group.

Of the total population, 420 patients (38.7%) had public insurance and eight patients (0.7%) had no insurance. The demographic characteristics of the study population according to insurance status are shown in Table 1. Significant differences in insurance were noted according to race/ethnicity with the public insurance group containing a higher proportion of Hispanic and African American patients. No statistically significant differences in distribution were found with

| TABLE 1 Demographic characteristics of cohort by insurance type |
|---------------------------------|
| **Low-income public insurance** |
| N = 428 | **Private insurance** |
| P |
| **Age (y)** | 21.2 (±10.75) | 22.4 (±10.78) | .06 |
| **Sex** | | | |
| Female | 163 (38.1%) | 298 (44.0%) | .075 |
| Male | 264 (61.7%) | 380 (56.1%) | |
| **Race/ethnicity** | | | |
| White, non-Hispanic | 154 (36%) | 455 (67.1) | <.001 |
| White, Hispanic | 188 (43.9%) | 98 (14.5%) | |
| African American | 30 (7.0%) | 24 (3.5%) | |
| Asian/Pacific Islander | 52 (12.2%) | 98 (14.5%) | |
| American Indian | 4 (0.9%) | 3 (0.4%) | |
regard to age, sex, or primary site. The tumor characteristics of the study population according to insurance status are shown in Table 2. A greater proportion of low-income public insurance patients presented with regional or metastatic disease than those patients with private insurance ($P < .001$). There was a higher proportion of bone tumors in the low-income public insurance group compared to the private insurance group ($P = .011$). The histologic subtypes that were represented and their relative proportions in the sample are shown in Table S1. The histologic subtypes with the highest representation in the sample were osteosarcoma (n = 232, 20.98%), rhabdomyosarcoma (n = 132, 11.9%), Ewing sarcoma (n = 113, 10.2%), and chondrosarcoma (n = 70, 6.3%).

### 3.2 Differences in overall survival by insurance

The 5- and 10-year OS rates for the entire cohort were 66% and 58%, respectively. There was a statistically significant difference in OS by insurance status (HR 1.26, 95% CI: 1.21-1.78, $P = .0001$, Figure 1); patients with low-income public insurance had significantly worse 5- and 10-year OS compared to those with private insurance (61% vs 71%, 49% vs 63%, respectively, $P = .0001$). When stratified by localized, regional, or metastatic disease, those with low-income public insurance had worse 5-year OS compared to those with private insurance across all three strata: localized (78% vs 84%), regional (64% vs 73%), and metastatic (23% vs 30%, $P < .0001$ for each comparison). These differences in survival persisted at 10 years: localized (60% vs 77%), regional (54% vs 63%), and metastatic (19% vs 30%, $P < .0001$ for each comparison) (Figure 2). There were no significant survival differences between the bone and soft tissue sarcoma groups (HR 0.92, 95% CI: 0.76-1.13, $P = .44$) irrespective of insurance status.

| TABLE 2 | Tumor characteristics of cohort by insurance type |
|---|---|---|
| **Low-income public insurance** (N = 428) | **Private insurance** (N = 678) | **P** |
| **Tissue origin** | | |
| Bone | 181 (42.3%) | 235 (34.7%) | .011 |
| Soft tissue | 247 (57.7%) | 443 (65.3%) | |
| **Primary site** | | |
| Non-pelvis | 362 (84.5%) | 570 (84.1%) | .82 |
| Pelvis | 66 (15.4%) | 108 (15.9%) | |
| **Stage at diagnosis** | | |
| Localized | 154 (36.0%) | 308 (45.4%) | <.001 |
| Regional | 115 (26.9%) | 164 (24.2%) | |
| Metastatic | 91 (21.3%) | 85 (12.5%) | |
| Unknown | 68 (15.9%) | 121 (17.8%) | |

### 3.3 Univariate and multivariable analyses

Race/ethnicity was not significantly associated with OS in univariate analysis. Significant univariate predictors of OS included male sex (HR = 1.26, 95% CI: 1.04-1.55, $P = .021$), age 15-29 at diagnosis (HR = 1.34, 95% CI 1.06-1.70, $P = .015$), regional disease at diagnosis (HR 1.50, 95% CI 1.15-1.95, $P = .002$), metastatic disease at diagnosis (HR 3.95, 95% CI 3.05-5.10, $P < .001$), and low-income public insurance (HR 1.46, 95% CI 1.20-1.78, $P < .001$). In multivariable analysis, the association of survival with male sex resolved when controlling for other factors. However, age 15-29 at diagnosis (HR = 1.38, 95% CI 1.08-1.75, $P = .009$), regional disease at diagnosis (HR 1.47, 95% CI 1.13-1.93, $P = .004$), metastatic disease at diagnosis (HR = 3.79, 95% CI 2.90-4.94, $P < .001$), and low-income public insurance (HR = 1.27, 95% CI 1.02-1.57, $P = .032$) remained significant independent predictors of OS (Table 3).

In subgroup analysis of patients with the four most common histologic subtypes (osteosarcoma, rhabdomyosarcoma, Ewing sarcoma, chondrosarcoma, n = 547), histologic subtype (osteosarcoma: HR 2.91, 95% CI 1.49-5.67, $P = .002$; rhabdomyosarcoma: HR 3.34, 95% CI 1.67-6.69, $P = .001$), age at diagnosis (age 15-29: HR 1.66, 95% CI 1.23-2.23, $P = .001$; age >29: HR 2.87, 95% CI 1.82-4.51, $P < .001$), metastatic disease at diagnosis (HR 3.8, 95% CI 2.57-5.63, $P < .001$), and low-income public insurance (HR 1.38, 95% CI 1.02-1.86, $P = .035$) were significant predictors of OS in multivariable analysis (Table S2).

Patients with low-income public insurance were more likely than those with private insurance to present with metastatic disease (OR 1.96, 95% CI 1.35-2.86, $P < .001$) after accounting for sex, age at diagnosis, and race/ethnicity. We did not find evidence of a statistically significant interaction between having low-income public insurance and stage of disease at diagnosis (Wald test $P = .60$). Mediation analysis indicates that metastatic disease at diagnosis mediates 15.3% (95% CI: 5%-34%) of the association between public insurance and OS. Corresponding results incorporating imputed data for missing disease stage at diagnosis were similar.

### 4 DISCUSSION

Our analyses demonstrate that pediatric, adolescent, and young adult bone and soft tissue sarcoma patients with public insurance had inferior OS compared to patients with private insurance. This survival disparity was noted irrespective of stage of disease at diagnosis. While patients with public insurance were more likely to present with metastatic disease at diagnosis, public insurance was
independently associated with diminished survival, even when controlling for sex, race/ethnicity, age, and stage of disease, as well as when stratified by stage of disease. In subgroup analysis, using the four most common histologic subtypes represented in the sample, public insurance remained independently associated with inferior survival even when controlled for histologic subtype, as well as sex, race/ethnicity, age, and stage of disease.

In this study, we used public insurance such as Medicaid as a proxy to identify low-income patients, as coverage is only available under California state law to individuals or families whose income is near the threshold for poverty. Studies of adult cancer have implicated SES in outcome disparities in a host of cancers, particularly those where availability of screening allows for early detection such as breast and colon cancer.25,26 Other authors have noted worse cancer outcomes in Medicaid recipients27,28 and have theorized that while access to screening and early detection may be a contributor, the disparities are more broadly attributable to social determinants of health,29 such as poverty itself. Patients who are enrolled in Medicaid often face a myriad of obstacles to medical care such as lack of transportation,30-32 lack of social support,33,34 lower health literacy,35-37 and lack of funds for deductibles and prescriptions.38 Additionally, Medicaid patients may be vulnerable to physiologic stressors, such food and housing insecurity39-41 and toxic stress, which affect their overall health status.42 However, our cancer registry lacks information related to individual socioeconomic characteristics such as income, education, and employment, which would assist in interrogating the association between public insurance and survival further.

Adolescents and young adults (AYA) aged 15-29 in our study had inferior survival compared with younger children and older adults, which is consistent with the current literature.33,44 The role of insurance in AYA cancer disparities has been explored by several authors, given the historical underinsurance of this age group.45 Previous studies have found that among young adults with cancer, private insurance coverage was associated with decreased likelihood of metastatic disease and death5,6; however, patients with public insurance were handled differently in each analysis. In explaining these inferior outcomes among the AYA population, researchers have postulated that lack of insurance

**FIGURE 1** Kaplan-Meier curves of overall survival by low-income insurance status among patients with bone and soft tissue sarcomas

**FIGURE 2** Kaplan-Meier curves of overall survival by low-income insurance status among patients with (A) localized, (B) regional, and (C) metastatic bone and soft tissue sarcomas
could result in diagnostic delays and subsequent presentation with later stage (and more difficult to treat) disease. In fact, Martin et al found that among young adults, health insurance type was significantly associated with lagtimes between onset of cancer symptoms and definitive diagnosis, and that longer lagtimes were associated with more advanced stage disease. The Affordable Care Act, which allows young adults to remain on their parents’ insurance plan until the age of 26 years, has the potential to improve access to medical care in this vulnerable group. While expansion of insurance access will likely affect population health positively, concurrent measures directed toward poverty eradication would likely have synergistic benefits for cancer outcomes.

Another possible mechanism for the inferior survival in those with public insurance could relate to receipt of insufficient treatment. Specifically, achievement of local control is of paramount importance in sarcoma management; however, the optimal mode of local control (surgical resection vs radiation) remains unclear. Previous studies have demonstrated racial disparities in receipt of surgical treatment for adult malignancies; in particular, a study of pediatric and young adult patients with chest wall sarcoma demonstrated racial disparities in receipt of surgical resection with associated inferior survival. Unfortunately, we lacked adequate data regarding treatment, such as method of local control, to ascertain whether there were treatment differences between insurance groups that could explain the noted disparities. Additionally, inferior access to care for complications of therapy and potentially increased risk of complications related to host factors (such as general nutritional status and the presence of medical comorbidities) could also influence survival.

Our data support the hypothesis that presentation with later stage disease partially mediates the relationship between low-income public insurance and death, as there was a clear association between public insurance and advanced stage disease. Furthermore, adjustment for stage of disease decreased the hazard ratio for the relationship between public insurance and survival. However, stage only partially explains this disparity, and cannot explain the inferior survival outcomes we noted among patients with localized or regional disease. It is possible that those patients with localized and regional disease received suboptimal treatment or disease surveillance, or were unable to adhere to recommended follow-up. In addition, our mediation analysis is vulnerable to unmeasured confounders, such as patient’s primary language, education, and indicators of individual- and community-level poverty, introducing bias.

While sample size and quality of curated, structured registry data are strengths of this study, several limitations should

| TABLE 3 | Univariate and multivariable Cox proportional hazard models evaluating the hazard of survival for patients with bone and soft tissue sarcomas |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| **Sex** | **Univariate** | **Multivariable** |
| | HR | 95% CI | P | HR | 95% CI | P |
| Female | Reference | | | Reference | | |
| Male | 1.26 | 1.04-1.55 | .021 | 1.06 | 0.84-1.34 | .59 |
| **Age at diagnosis** | **Univariate** | **Multivariable** |
| | HR | 95% CI | P | HR | 95% CI | P |
| <15 | Reference | | | Reference | | |
| 15-29 | 1.34 | 1.06-1.70 | .015 | 1.38 | 1.08-1.75 | .009 |
| >29 | 1.00 | 0.78-1.28 | .982 | 1.09 | 0.85-1.41 | .50 |
| **Race/ethnicity** | **Univariate** | **Multivariable** |
| | HR | 95% CI | P | HR | 95% CI | P |
| NHW | Reference | | | Reference | | |
| All other race/ethnicities | 1.07 | 0.88-1.30 | .473 | 0.96 | 0.78-1.19 | .71 |
| **Stage** | **Univariate** | **Multivariable** |
| | HR | 95% CI | P | HR | 95% CI | P |
| Local | Reference | | | Reference | | |
| Regional | 1.50 | 1.15-1.95 | .002 | 1.47 | 1.13-1.93 | .004 |
| Metastatic | 3.95 | 3.05-5.10 | <.001 | 3.79 | 2.90-4.94 | <.001 |
| **Insurance status** | **Univariate** | **Multivariable** |
| | HR | 95% CI | P | HR | 95% CI | P |
| Private insurance | Reference | | | Reference | | |
| Low-income public insurance | 1.46 | 1.20-1.78 | <.001 | 1.27 | 1.02-1.57 | .032 |

Bold text indicates a statistically significant difference with a P value less than .05.
be mentioned. Within our data, the rate of uninsurance (<1% of total sample) is lower than what has been described in the literature, and may be explained by insurance enrollment at diagnosis. Moreover, insurance status is vulnerable to misclassification, as individuals may be retroactively enrolled on Medicaid at diagnosis. This misclassification may be differential if those with more advanced disease were more likely to be uninsured. This misclassification could suggest that an association exists between low-income public insurance and metastatic disease, when truly uninsured was the driver. Prior studies have reported that uninsured patients have distinctly inferior outcomes compared with those with public or private insurance. Because public insurance has been handled differently by different authors, the existing literature is difficult to extrapolate; risks associated with discrete insurance types should be queried in future studies. Additionally, the lack of reliable treatment detail in our data makes a deeper understanding of the mechanism behind the association between public insurance and survival difficult to discern.

Our findings demonstrate that public insurance is a strong independent risk factor for advanced disease at diagnosis and inferior OS among pediatric, adolescent, and young adults with bone and soft tissue sarcoma. While the survival disparity is partially mediated by advanced disease at diagnosis, other mechanisms likely explain the residual disparity. Additional studies to evaluate other mechanisms that underlie the survival disparity are essential in order to target interventions to the appropriate contributing factors. In particular, the role of poverty in pediatric cancer disparities merits further investigation.

ACKNOWLEDGMENTS
We acknowledge the University of California San Francisco Cancer Registry and Dr Ann Griffin, and Swim Across America.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID
Neela L. Penumarthy https://orcid.org/0000-0002-3373-3863
Lena E. Winestone https://orcid.org/0000-0001-9982-1594

REFERENCES
1. Bhatia S. Disparities in cancer outcomes: lessons learned from children with cancer. Pediatr Blood Cancer. 2011;56(6):994-1002.
2. Worch J, Matthey KK, Neuhaus J, Goldsby R, DuBois SG. Ethnic and racial differences in patients with Ewing sarcoma. Cancer. 2010;116(4):983-988.
3. Jacobs AJ, Lindholm EB, Levy CF, Fish JD, Glick RD. Racial and ethnic disparities in treatment and survival of pediatric sarcoma. J Surg Res. 2017;219:43-49.
4. Koohbanani B, Han G, Reed D, et al. Ethnicity and age disparities in Ewing sarcoma outcome. Fetal Pediatr Pathol. 2013;32(4):246-252.
5. Aizer AA, Falbit B, Mendu ML, et al. Cancer-specific outcomes among young adults without health insurance. J Clin Oncol. 2014;32(19):2025-2030.
6. Rosenberg AR, Koon L, Chen L, Li CI, Jones B. Insurance status and risk of cancer mortality among adolescents and young adults. Cancer. 2015;121(8):1279-1286.
7. Markt SC, Lago-Hernandez CA, Miller RE, et al. Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors. Cancer. 2016;122(20):3127-3135.
8. Robbins AS, Lerro CC, Barr RD. Insurance status and distant-stage disease at diagnosis among adolescent and young adult patients with cancer aged 15 to 39 years: National Cancer Data Base, 2004 through 2010. Cancer. 2014;120(8):1212-1219.
9. Martin S, Ulrich C, Munsell M, Taylor S, Lange B, Bleyer A. Delays in cancer diagnosis in underinsured young adults and older adolescents. Oncologist. 2007;12(7):816-824.
10. Abrahao R, Ribeiro RC, Mediureis BC, Keogh RH, Keegan TH. Disparities in early death and survival in children, adolescents, and young adults with acute promyelocytic leukemia in California. Cancer. 2015;121(22):3990-3997.
11. HaDuong JH, Martin AA, Skape SX, Mascarenhas L. Sarcomas. Pediatr Clin North Am. 2015;62(1):179-200.
12. Pastore G, Peris-Bonet R, Carli M, Martinez-García C, de Toledo JS, Stellaro-Foucher E. Childhood soft tissue sarcomas incidence and survival in European children (1978–1997): Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):2136-2149.
13. Joshi D, Anderson JR, Paidas C, Breneman J, Parham DM, Crist W. Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Pediatr Blood Cancer. 2004;42(1):64-73.
14. Crist WM, Kun LE. Common solid tumors of childhood. N Engl J Med. 1991;324(7):461-471.
15. Rudowitz R, Artiga S, Rachel A. Children’s Health Coverage: Medicaid, CHIP, and the ACA. Henry J Kaiser Family Foundation; 2014. https://www.kff.org/wp-content/uploads/2014/03/8570-children_s-health-coverage-medicaid-chip-and-the-aca1.pdf. Accessed March 15, 2019.
16. Foundation HJKF. Where are States Today? Medicaid and CHIP Eligibility Levels for Children, Pregnant Women, and Adults. 2018. https://www.kff.org/medicaid/fact-sheet/where-are-states-today-medicaid-and-chip/. Accessed March 15, 2019.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
18. Cox DR. Regression models and life-tables. J R Stat Soc Ser B (Methodol). 1972;34(2):187-202.
19. Sterne JAC, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393.
20. Falcaro M, Nur U, Rachet B, Carpenter JR. Estimating excess hazard ratios and net survival when covariate data are missing: strategies for multiple imputation. Epidemiology. 2015;26(3):421-428.
21. Eisemann N, Waldmann A, Katalinic A. Imputation of missing values of tumour stage in population-based cancer registration. *BMC Med Res Methodol*. 2011;11:129.

22. Luo Q, Egger S, Yu XQ, Smith DP, O’Connell DL. Validity of using multiple imputation for "unknown" stage at diagnosis in population-based cancer registry data. *PLoS ONE*. 2017;12(6):e0180033.

23. Imai K, Keele L, Tingley D. A general approach to causal mediation analysis. *Psychol Methods*. 2010;15(4):309-334.

24. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. *J Pers Soc Psychol*. 1986;51(6):1173-1182.

25. Hendren S, Chiu N, Fisher S, et al. Patients’ barriers to receipt of cancer care, and factors associated with needing more assistance from a patient navigator. *J Natl Med Assoc*. 2011;103(8):701-710.

26. Tangka FK, Subramanian S, Mobley LR, et al. Racial and ethnic disparities among state Medicaid programs for breast cancer screening. *Prev Med*. 2017;102:59-64.

27. Mobley LR, Subramanian S, Tangka FK, et al. Breast cancer screening among women with medicaid, 2006–2008: a multilevel analysis. *J Racial Ethn Health Disparities*. 2017;4(3):446-454.

28. Koroukian SM, Bakaki PM, Htoo PT, et al. The Breast and Cervical Cancer Early Detection Program, Medicaid, and breast cancer outcomes among Ohio’s underserved women. *Cancer*. 2017;123(16):3097-3106.

29. Abdelsattar ZM, Hendren S, Wong SL. The impact of health insurance on cancer care in disadvantaged communities. *Cancer*. 2017;123(7):1219-1227.

30. McKernan SC, Reynolds JC, Ingleshwar A, et al. Patients’ barriers to receipt of cancer care and factors associated with needing more assistance from a patient navigator. *J Natl Med Assoc*. 2011;103(8):701-710.

31. Syed ST, Gerber BS, Sharp LK. Traveling towards disease: transportation barriers to health care access. *J Community Health*. 2013;38(5):976-993.

32. Diamant AL, Hays RD, Morales LS, et al. Delays and unmet need for health care among adult primary care patients in a restructured urban public health system. *Am J Public Health*. 2004;94(5):783-789.

33. Enard KR, Nevaraz L, Ganelin DM. Association between perceived discrimination and emergency department use among safety-net patients in the Southwestern United States. *South Med J*. 2018;111(1):1-7.

34. Galea S, Tracy M, Hoggat KJ, Dimaggio C, Karpati A. Estimated deaths attributable to social factors in the United States. *South Med J*. 2014;32(28):3118-3125.

35. Sentell T. Implications for reform: survey of California adults suggests low health literacy predicts likelihood of being uninsured. *Health Aff (Millwood)*. 2012;31(5):1039-1048.

36. Sentell T, Zhang W, Ching LK. Insights in Public Health: The importance of considering educational inequity and health literacy to understand racial/ethnic health disparities. *Hawaii J Med Public Health*. 2015;74(4):244-247.

37. Abrams MA, Klass P, Dreyer BP. Health literacy and children: introduction. *Pediatrics*. 2009;124(Suppl 3):S262-264.

38. Doshi JA, Li P, Desai S, Marcus SC. Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia. *J Med Econ*. 2017;20(12):1252-1260.

39. Afufulani P, Herman D, Coleman-Jensen A, Harrison GG. Food insecurity and health outcomes among older adults: the role of cost-related medication underuse. *J Nutr Gerontol Geriatr*. 2015;34(3):319-342.

40. Herman D, Afufulani P, Coleman-Jensen A, Harrison GG. Food insecurity and cost-related medication underuse among nonelderly adults in a nationally representative sample. *Am J Public Health*. 2015;105(10):e48-59.

41. Food insecurity: a public health issue. *Public Health Rep*. 2016;131(5):655-657.

42. Dowd MD. Early adversity, toxic stress, and resilience: pediatrics for today. *Pediatr Ann*. 2017;46(7):e246-e249.

43. Bleyer A. The adolescent and young adult gap in cancer care and outcome. *Curr Probl Pediatr Adolesc Health Care*. 2005;35(5):182-217.

44. Group AaYAOPR. Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer. In: Health Nlo, ed. Bethesda, MD: National Institutes of Health. NIH Publication No 06-6067; 2006.

45. Bureau USC. *Current Population Survey Tables for Health Insurance Coverage*. United States Census Bureau. https://www.census.gov/data/tables/time-series/demo/income-poverty/cps-hi.html. Accessed March 15, 2019.

46. Parsons HM, Schmidt S, Tenner LL, Bang H, Kegeman TH. Early impact of the Patient Protection and Affordable Care Act on insurance among young adults with cancer: analysis of the dependent insurance provision. *Cancer*. 2016;122(11):1766-1773.

47. Nystrom L, Reimer NB, Reith JD, et al. Multidisciplinary management of soft tissue sarcoma. *ScientificWorldJournal*. 2013;2013:852462.

48. DuBois SG, Krailo MD, Gebhardt MC, et al. Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children’s Oncology Group. *Cancer*. 2015;121(3):467-475.

49. Revels SL, Banerjee M, Yin H, Sonnenday CJ, Birkmeyer JD. Racial disparities in surgical resection and survival among elderly patients with poor prognosis cancer. *J Am Coll Surg*. 2013;216(2):312-319.

50. Shah A, Chao KSC, Ostbye T, et al. Trends in racial disparities in pancreatic cancer surgery. *J Gastrointest Surg*. 2013;17(11):1897-1906.

51. Joseph M, Hamilton EC, Hayes-Jordan A, Huh WW, Austin MT. The impact of racial/ethnic disparities on survival for children and young adults with chest wall sarcoma: a population-based study. *J Pediatr Surg*. 2018;53(8):1621-1626.

52. Walker GV, Grant SR, Guadagnolo BA, et al. Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status. *J Clin Oncol*. 2014;32(28):3118-3125.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

---

**How to cite this article**: Penumarthi NL, Goldsby RE, Shiboski SC, Wustrack R, Murphy P, Winestone LE. Insurance impacts survival for children, adolescents, and young adults with bone and soft tissue sarcomas. *Cancer Med*. 2020;9:951–958. [https://doi.org/10.1002/cam4.2739](https://doi.org/10.1002/cam4.2739)